MedDataX Logo

Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis

NCT ID: NCT02840331

Last Updated: 2017-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-31

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study would examine by hypericin-supported Fluoreszenzlaparoskopy in terms of tumor size, number and location of the combination of photodynamic diagnosis (PDD) and therapy (PDT) with regard to the detection of peritoneal metastases of locally advanced gastric cancer at 50 adult patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypericin-PDT study is an examination of patients with gastric cancer. The peritoneal carcinosis (PC) of the adult represents the final stage of an advanced tumor and was treated in the past, usually by means of palliative chemotherapy. An improvement in survival for patients with PC could be further improved through the use of maximum cytoreductive surgery (CRS) can be achieved with radical removal of the entire tumor mass and the combination of CRS and intraperitoneal hyperthermic chemotherapy (HIPEC) event-free survival and overall survival. A cure of patients is achieved only in the rarest cases. An essential problem in the treatment of peritoneal carcinomatosis is that can only be poorly differentiated from surrounding tissue due to their location, the tumors often not well recognized because of their size or. This results to differ (as scar tissue) for the surgeon the difficulty between eigentlichem tumor tissue and surrounding tissue.

Through the use of innovative diagnostic and therapeutic options (for example, photodynamic diagnosis (PDD) and therapy (PDT)) above mentioned problems can be improved. In photodynamic diagnosis contrast between tumor and surrounding healthy tissue is improved by an interaction of photodynamic active substance with light of a particular wavelength. The PDT is based on a topical or systemic administration of a photosensitizer (here hypericin), which is irradiated with light of a suitable wavelength and in the presence of oxygen oxygen radicals (with the consequence of a direct cytotoxicity of the tumor cells leading) forms.

The study will be carried out in the Department of General, Visceral and Transplantation Surgery Tübingen at 50 adult patients. The study proposed would examine by hypericin-supported Fluoreszenzlaparoskopy in terms of tumor size, number and location of the combination of photodynamic diagnosis (PDD) and therapy (PDT) with regard to the detection of peritoneal metastases of locally advanced gastric cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peritoneal Carcinomatosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Gastric carcinoma Peritoneal carcinomatosis Photodynamic diagnosis Photodynamic therapy St. John's Wort Peritoneal metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

St. John's Wort & PDD, PDT

St. John's Wort 900 milligram once oral preoperative \& intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes

Group Type EXPERIMENTAL

St. John's Wort

Intervention Type DRUG

Single oral doses (900 milligram) 2-4 hours before laparoscopy

Photodynamic diagnostic and therapy

Intervention Type DEVICE

Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

St. John's Wort

Single oral doses (900 milligram) 2-4 hours before laparoscopy

Intervention Type DRUG

Photodynamic diagnostic and therapy

Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Laif 900

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years
* Computertomography - morphologically locally - advanced gastric cancer (Classification of Malignant Tumours (TNM): size or direct extent of the primary tumor \> 3 or degree of spread to regional lymph nodes positive) without distant metastases (except peritoneum)
* Histologically confirmed adenocarcinoma of the stomach
* Karnofsky Index \> 70

Exclusion Criteria

* Patients who are considered inoperable because of a reduced general condition:

* Congestive heart failure (New York Heart Association (NYHA) Functional Classification III / IV),
* Severe coronary heart disease, non-treatable arrhythmia or non-adjustable hypertension,
* Severe asthma suffering (Chronic obstructive pulmonary disease)
* Distant metastases except peritoneum
* Patients with a contraindication related to the present study
* Allergy or intolerance to the study drug or a substance with chemical similarity to the study medication.
* Lack of capacity to consent
* Participation in another interventional therapy studies at intervals of 30 days
* Contraindication to taking the prescribed study medication the physician's discretion
* Pregnancy/ Breastfeeding
* Women in childbearing age who refuse:

* Simultaneously apply two appropriate contraceptive measures or maintain a full hetero-sexual abstinence at least 28 days prior to the study and for at least 28 days after administration of study medication
* To stop breast-feeding during the study and through 6 months after the end of study
* Men who refuse:

\- To use a latex condom during any sexual contact with childbearing women during the study and at least 28 days after completion of study, even if they are successful vasectomy.
* \- Sperm donor to make up at least 28 days after completion of study.-
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Tuebingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Dr. Stefan Beckert

Chief consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefan Beckert, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University Department of General, Visceral and Transplant Surgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Department of General, Visceral and Transplant Surgery

Tübingen, Baden.Württemberg, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stefan Beckert, Prof. Dr.

Role: CONTACT

Phone: +49-(0)7071-29-81222

Email: [email protected]

Alfred Königsrainer, Prof. Dr.

Role: CONTACT

Phone: +49-(0)7071-29-81222

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stefan Beckert, Prof. Dr.

Role: primary

Alfred Königsrainer, Prof. Dr.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Hypericin-PDT

Identifier Type: -

Identifier Source: org_study_id